TAL Education Group's stock soared following robust Q3 FY2026 results and a new share repurchase program, marking a potential inflection point for the Chinese tutoring giant navigating a post-regulatory landscape. Analysts debate if the rally signals a lasting recovery or a temporary reprieve.
LVMH's wine and spirits arm, led by Hennessy, faces a sharp profit decline amid weak U.S. and Chinese demand, while Rémy Cointreau reports a modest rebound in Cognac sales, highlighting a divided market outlook.
Despite a challenging year that saw Nike's shares fall sharply, a majority of analysts maintain a cautiously optimistic outlook, betting on the sportswear giant's long-term brand strength and innovation pipeline to fuel a recovery.
As artificial intelligence reshapes the competitive landscape, tech leaders face a stark choice: disrupt their own profitable core businesses or risk being left behind. New financial results from Microsoft, Meta, and Tesla reveal the high-stakes strategies—and market reactions—defining this pivotal moment.
The global container shipping giant Ocean Network Express reported a net loss for its third fiscal quarter, citing soft demand and declining freight rates, particularly on key Asia-U.S. and Asia-Europe routes. The carrier anticipates a gradual recovery in the coming months.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
KeyBanc Capital Markets has upgraded LivaNova PLC (LIVN) from Sector Weight to Overweight, setting an $81 price target. The move reflects a broader positive shift in analyst sentiment towards the medical technology sector as valuation premiums ease.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
Goldman Sachs and Evercore ISI analysts have raised price targets for GE HealthCare Technologies (GEHC), citing a projected market recovery and strong capital expenditure trends by 2026. The medical devices firm is highlighted as a top hedge fund pick.
Fueled by surging global demand for its Hoka and Ugg brands, Deckers Outdoor Corp. posted a robust third-quarter performance that surpassed expectations, driving its stock price up sharply and assuaging recent Wall Street concerns over growth sustainability.
Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.
U.S. equity markets slipped Thursday as Treasury yields climbed following President Trump's announcement that he will nominate former Fed Governor Kevin Warsh as the next central bank chair. The move, seen as potentially less dovish, overshadowed positive economic data and corporate earnings.
Panama's Supreme Court has declared CK Hutchison's concession to operate the Balboa and Cristóbal ports unconstitutional, derailing a major sale and placing APM Terminals in temporary control. The ruling intensifies geopolitical tensions over control of the strategic Panama Canal.
President Trump nominates Kevin Warsh, a former Fed governor with a history of advocating for lower interest rates and expressing favorable views on Bitcoin, to lead the Federal Reserve, a move that could reshape monetary policy and digital asset markets.
President Trump's dismissal of concerns over the dollar's decline has accelerated a sell-off, sending the greenback to multi-year lows and triggering record-breaking rallies in gold and silver as markets question U.S. currency policy.
